• SENSEX
    NIFTY 50

CLSA gives 'buy' rating for Dr Reddy’s Laboratories

Updated : April 07, 2021 02:00 PM IST

The brokerage firm states that the management aspires for sustainable 25 percent EBITDA margins
The keys to achieving this goal, according to CLSA, are improved profitability in India, along with sustaining current US margins
CLSA gives 'buy' rating for Dr Reddy’s Laboratories
Published : April 07, 2021 02:00 PM IST

You May Also Like

Live TV

recommended for you

Advertisement